Search results
Oxford Nanopore Eyes TB Drug Resistance for First In-House-Developed Diagnostic Test
GenomeWeb News· 2 days agoOxford Nanopore Technologies has been working on a tuberculosis drug resistance sequencing assay that it hopes will become its first in vitro diagnostic ...
Antibiotic resistance causing large avoidable death toll, doctors say
dpa international via Yahoo News· 2 days agoAround 750,000 of the almost 5 million annual deaths caused by antimicrobial resistance - when...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 5 days agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk ...
Delhi HC closes PIL on medicine shortage in Rajan Babu Institute after govt's assurance
Investing.com· 2 days agoThe decision came after a division bench of Acting Chief Justice Manmohan and Justice Manmeet PS...
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance...
Benzinga· 5 days agoFindings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab[1],[2]Data from a
Over 750,000 antimicrobial resistance deaths preventable yearly via vaccines, water, sanitation and...
Medical Xpress· 2 days agoAuthors say if the world does not prioritize action on AMR now, we will see a steady increase in the...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved...
WTRF Wheeling· 4 days agoIn Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically ...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
KTLA-TV Los Angeles· 2 days agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...
ADA2 regulates inflammation and hematopoietic stem cell emergence via the A2bR pathway in zebrafish...
Nature· 3 days agoA DADA2 zebrafish model with cecr1b deficiency was generated. Characterization of hematopoietic processes revealed a role of Cecr1b in regulating inflammation and hematopoietic stem cell production through the A2br-mediated adenosine signaling.